Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

She’s racing to a run-through for a 14-course tasting menu she will barely nibble at as she raves about her weight loss on ...

Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

Relying solely on BMI to diagnose obesity may be outdated, say global experts. A new report calls for a more comprehensive ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...

Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant lowered its 2024 full-year forecast. Monitor these key price levels.

Wall Street investors, spurred on by Trump's pro-business agenda, could be ignoring real risks posed by the president.

Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 ...

The following chart highlights the basics of Mounjaro ... has been approved by the FDA to help with weight loss and weight management. Zepbound and Mounjaro have the same active drug, tirzepatide.

This figure is $400 million below the low end of the company’s prior guidance and includes $3.5 billion from its type 2 ...